Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 101 to 110 of 1090 total matches.
Cabtreo: A Three-Drug Gel for Acne
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024 (Issue 1700)
of skin
(avoiding the nipple and areola) and for the shortest
duration possible.
DRUG INTERACTIONS ...
The FDA has approved Cabtreo (Bausch Health), a gel
containing the retinoid adapalene, the oxidizing agent
benzoyl peroxide, and the antibiotic clindamycin, for
treatment of acne vulgaris in patients ≥12 years old.
Cabtreo is the first three-drug topical formulation to
become available in the US for treatment of acne.
Med Lett Drugs Ther. 2024 Apr 15;66(1700):59-60 doi:10.58347/tml.2024.1700b | Show Introduction Hide Introduction
Gluten-Free Drugs for Celiac Disease Patients
The Medical Letter on Drugs and Therapeutics • Mar 10, 2008 (Issue 1281)
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D.,University of Washington
ADVISORY BOARD ...
Celiac disease is a chronic autoimmune disorder caused by a genetic intolerance to gluten that occurs in about 1% of the population. The main form of treatment is a lifelong gluten-free diet.
Cangrelor (Kengreal) - An IV Antiplatelet Drug for PCI
The Medical Letter on Drugs and Therapeutics • Oct 26, 2015 (Issue 1480)
in cangrelor-treated patients (1.2% vs 0.3%).
DRUG INTERACTIONS — When cangrelor was
administered ...
The FDA has approved cangrelor (Kengreal – The
Medicines Company), an IV P2Y12 platelet inhibitor,
as an adjunct to percutaneous coronary intervention
(PCI) in patients who have not been pretreated with a
P2Y12 inhibitor and are not being given a glycoprotein
IIb/IIIa inhibitor.
Drugs for Sexually Transmitted Infections
The Medical Letter on Drugs and Therapeutics • Jun 27, 2022 (Issue 1653)
Drugs for Sexually Transmitted Infections ...
This article includes recommendations for management
of most sexually transmitted infections (STIs)
other than HIV and viral hepatitis. Some of the
indications and dosages recommended here have
not been approved by the FDA (see Table 1).
Triumeq: A 3-Drug Combination for HIV
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015 (Issue 1459)
pregnancy.
DRUG INTERACTIONS – Drugs containing polyvalent
cations (sucralfate, buffered medications ...
The FDA has approved Triumeq (Viiv Healthcare),
a fixed-dose combination of the integrase strand
transfer inhibitor (INSTI) dolutegravir and the
nucleoside reverse transcriptase inhibitors (NRTIs)
abacavir and lamivudine, for once-daily treatment of
HIV-1 infection. Dolutegravir (Tivicay) was approved
as a single agent in 2013.
In Brief: Three New Injectable Antipsychotic Drugs
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
adjustments may be needed for renal or hepatic impairment or for drug interactions.
2. Initial dosage of long ...
Three extended-release injectable formulations of
second-generation antipsychotic drugs — two of
risperidone (Rykindo, Uzedy) and one of aripiprazole
(Abilify Asimtufii) — have been approved by the FDA
for treatment of schizophrenia in adults. Rykindo and
Abilify Asimtufii are also approved for maintenance
treatment of bipolar I disorder in adults. Other
extended-release injectable formulations of
risperidone and aripiprazole have been available in
the US for years (see Table 1).
Med Lett Drugs Ther. 2023 Dec 25;65(1692):207-8 doi:10.58347/tml.2023.1692d | Show Introduction Hide Introduction
Two New Drugs for Idiopathic Pulmonary Fibrosis
The Medical Letter on Drugs and Therapeutics • Dec 08, 2014 (Issue 1457)
or treatment interruption
may be required.
DRUG INTERACTIONS — Pirfenidone is primarily
metabolized ...
The FDA has approved 2 oral drugs for treatment
of idiopathic pulmonary fibrosis (IPF). Pirfenidone
(Esbriet) has been available in Europe since 2011 and
in Canada since 2012. Nintedanib (Ofev) is available
only in the US.
Rilpivirine (Edurant) - A New Drug for HIV Infection
The Medical Letter on Drugs and Therapeutics • Aug 22, 2011 (Issue 1371)
as category B (no evidence of risk in animals)
for use during pregnancy.
DRUG INTERACTIONS — Taking ...
The FDA has approved rilpivirine (Edurant –
Janssen), a non-nucleoside reverse transcriptase
inhibitor (NNRTI), for use with other antiretroviral
agents for treatment of HIV-1 infection in treatment-naive
adults. Rilpivirine is also available in a fixed-dose
combination with emtricitabine and tenofovir
(Complera – Gilead).
Expanded Table: Some Drugs for Management of Opioid Withdrawal Symptoms (online only)
The Medical Letter on Drugs and Therapeutics • Aug 27, 2018 (Issue 1554)
Initial
Target Dosage Adverse Effects Drug Interactions Pregnancy/Lactation Comments
Cost1
Opioids ...
View Expanded Table: Some Drugs for Management of Opioid Withdrawal Symptoms
Drugs for Bacterial Infections
Treatment Guidelines from The Medical Letter • Jul 01, 2013 (Issue 131)
. Quinupristin/dalfopristin, which is not commonly
used because of its toxicity and drug interactions ...
The text that follows reviews some common bacterial
infections and their empiric treatment pending the
results of culture and susceptibility testing. The recommendations
made here are based on the results of
susceptibility studies, clinical trials, and the opinions
of Medical Letter reviewers. Tables 1 and 2 list the usual
dosages of antibacterial drugs.